Structure-activity relationship and in vitro and in vivo evaluation of the potent cytotoxic anti-microtubule agent N-(4-methoxyphenyl)-N,2,6-trimethyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride and its analogues as antitumor agents

Journal of Medicinal Chemistry

Volumn 56, Issue 17, 2013, Pages 6829-6844

  Gangjee, Aleem ^a   Zhao, Ying ^a   Raghavan, Sudhir ^a   Rohena, Cristina C ^b   Mooberry, Susan L ^c   Hamel, Ernest ^d  

^a DUQUESNE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c University of Texas Health Science Center at San Antonio   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 METHYL 3,5,6,7 4 HYDRO 4H CYCLOPENTA[D]PYRIMIDIN 4 ONE; 2 AMINO 6 VINYL 6,7 DIHYDRO 3H CYCLOPENTA[D]PYRIMIDIN 4(5H) ONE; 2 AMINO N (4 METHOXYPHENYL) N,6 DIMETHYL 6,7 DIHYDRO 5H CYCLOPENTA[D]PYRIMIDIN 4 AMINIUM CHLORIDE; 2 METHYL 6 VINYL 6,7 DIHYDRO-3H CYCLOPENTA[D]PYRIMIDIN 4(5H) ONE; 2,5 DIMETHYL 6,7 DIHYDRO 3H CYCLOPENTA[D]PYRIMIDIN 4(5H) ONE; 3 VINYLHEXANEDIOIC ACID; 4 CHLORO 2 METHYL 6 VINYL 6,7 DIHYDRO 5H CYCLOPENTA[D]PYRIMIDINE; 4 CHLORO 2,5 DIMETHYL 6,7 DIHYDRO 5H CYCLOPENTA[D]PYRIMIDINE; 4 CHLORO 6 METHYL 6,7 DIHYDRO 5H CYCLOPENTA[D]PYRIMIDIN 2 AMINE; 4 CHLORO 6 VINYL 6,7 DIHYDRO 5H CYCLOPENTA[D]PYRIMIDIN 2 AMINE; 4 VINYLCYCLOHEXANE 1,2 DIOL; ANTINEOPLASTIC AGENT; BETA III TUBULIN; BETA TUBULIN; DIMETHYL 3 VINYLHEXANEDIOATE; METHYL 2 DIAZO 3 OXOHEPTANOATE; MULTIDRUG RESISTANCE PROTEIN; N (3 BROMOPHENYL) N,2,6 TRIMETHYL 6,7 DIHYDRO 5H CYCLOPENTA[D]PYRIMIDIN 4 AMNIUM CHLORIDE; N (4 CHLOROPHENYL) N,2,6 TRIMETHYL 6,7 DIHYDRO 5H CYCLOPENTA[D]PYRIMIDIN 4 AMINIUM CHLORIDE; N (4 METHOXYPHENYL) N ,2,6 TRIMETHYL-6,7 DIHYDRO 5H CYCLOPENTA[D]PYRIMIDIN 4 AMINIUM CHLORIDE DERIVATIVE; N (4 METHOXYPHENYL) N,2 DIMETHYL 6 VINYL 6,7 DIHYDRO 5H CYCLOPENTA[D]PYRIMIDIN 4 AMINE; N (4 METHOXYPHENYL) N,2,5 TRIMETHYL 6,7 DIHYDRO 5H CYCLOPENTA[D]PYRIMIDIN 4 AMINIUM CHLORIDE; N 4 (4 METHOXYPHENYL) 6 METHYL 6,7 DIHYDRO 5H CYCLOPENTA[D]PYRIMIDINE 2,4 DIAMINE; N 4 (4 METHOXYPHENYL) N 4 ,6 DIMETHYL 6,7 DIHYDRO 5H CYCLOPENTA[D]PYRIMIDIN 2,4 DIAMINE; N 4 (4 METHOXYPHENYL) N 4 METHYL 6 VINYL 6,7 DIHYDRO 5H CYCLOPENTA[D]PYRIMIDIN 2,4 DIAMINE; N,2,6 TRIMETHYL N [4 (METHYLTHIO)PHENYL)] 6,7 DIHYDRO 5H CYCLOPENTA[D]PYRIMIDIN 4 AMINIUM CHLORIDE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TRIPLE NEGATIVE BREAST CANCER;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84884221975     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400639z     Document Type: Article

References (43)

1. Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs Nat. Rev. Cancer 2004, 4, 253-265
2. Risinger, A. L.; Giles, F. J.; Mooberry, S. L. Microtubule dynamics as a target in oncology Cancer Treat Rev. 2009, 35, 255-261
3. Dumontet, C.; Jordan, M. A. Microtubule-binding agents: A dynamic field of cancer therapeutics Nat. Rev. Drug Discovery 2010, 9, 790-803
4. Jordan, M. A.; Kamath, K. How do microtubule-targeted drugs work? An overview Curr. Cancer Drug Targets 2007, 7, 730-742
5. Zhou, J.; Giannakakou, P. Targeting microtubules for cancer chemotherapy Curr. Med. Chem. Anti-Cancer Agents 2005, 5, 65-71
6. Morris, P. G.; Fornier, M. N. Microtubule active agents: Beyond the taxane frontier Clin. Cancer Res. 2008, 14, 7167-7172
7. Ravelli, R. B.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain Nature 2004, 428, 198-202
8. Kanthou, C.; Tozer, G. M. Microtubule depolymerizing vascular disrupting agents: Novel therapeutic agents for oncology and other pathologies Int. J. Exp. Pathol. 2009, 90, 284-294
9. Vincent, L.; Kermani, P.; Young, L. M.; Cheng, J.; Zhang, F.; Shido, K.; Lam, G.; Bompais-Vincent, H.; Zhu, Z.; Hicklin, D. J.; Bohlen, P.; Chaplin, D. J.; May, C.; Rafii, S. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling J. Clin. Invest. 2005, 115, 2992-3006
10. Chaplin, D. J.; Horsman, M. R.; Siemann, D. W. Current development status of small-molecule vascular disrupting agents Curr. Opin. Invest. Drugs 2006, 7, 522-528
11. Carlson, R. O. New tubulin targeting agents currently in clinical development Expert Opin. Invest. Drugs 2008, 17, 707-722
12. Fojo, T.; Menefee, M. Mechanisms of multidrug resistance: The potential role of microtubule-stabilizing agents Ann. Oncol. 2007, 18, v3-8
13. Yeh, J. J.; Hsu, W. H.; Wang, J. J.; Ho, S. T.; Kao, A. Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression Respiration 2003, 70, 32-35
14. Kruh, G. D.; Belinsky, M. G. The MRP family of drug efflux pumps Oncogene 2003, 22, 7537-7552
15. Leonard, G. D.; Fojo, T.; Bates, S. E. The role of ABC transporters in clinical practice Oncologist 2003, 8, 411-424
16. Ling, V. Multidrug resistance: Molecular mechanisms and clinical relevance Cancer Chemother. Pharmacol. 1997, 40, S3-8
17. Shen, H.; Lee, F. Y.; Gan, J. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2) J. Pharmacol. Exp. Ther. 2011, 337, 423-432
18. Gan, P. P.; McCarroll, J. A.; Po'uha, S. T.; Kamath, K.; Jordan, M. A.; Kavallaris, M. Microtubule dynamics, mitotic arrest, and apoptosis: Drug-induced differential effects of betaIII-tubulin Mol. Cancer Ther. 2010, 9, 1339-1348
19. Dumontet, C.; Isaac, S.; Souquet, P. J.; Bejui-Thivolet, F.; Pacheco, Y.; Peloux, N.; Frankfurter, A.; Luduena, R.; Perol, M. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy Bull. Cancer 2005, 92, E25-30
20. Seve, P.; Isaac, S.; Tredan, O.; Souquet, P. J.; Pacheco, Y.; Perol, M.; Lafanechere, L.; Penet, A.; Peiller, E. L.; Dumontet, C. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy Clin. Cancer Res. 2005, 11, 5481-5486
21. Hasegawa, S.; Miyoshi, Y.; Egawa, C.; Ishitobi, M.; Taguchi, T.; Tamaki, Y.; Monden, M.; Noguchi, S. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers Clin. Cancer Res. 2003, 9, 2992-2997
22. Stengel, C.; Newman, S. P.; Leese, M. P.; Potter, B. V.; Reed, M. J.; Purohit, A. Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents Br. J. Cancer 2010, 102, 316-324
23. Gangjee, A.; Zhao, Y.; Hamel, E.; Westbrook, C.; Mooberry, S. L. Synthesis and biological activities of (R)- and (S)- N -(4-methoxyphenyl)- N,2,6-trimethyl-6,7-dihydro-5 H -cyclopenta[ d ]pyrimidin-4-aminium chloride as potent cytotoxic antitubulin agents J. Med. Chem. 2011, 54, 6151-6155
24. Gangjee, A.; Zhao, Y.; Lin, L.; Raghavan, S.; Roberts, E. G.; Risinger, A. L.; Hamel, E.; Mooberry, S. L. Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance J. Med. Chem. 2010, 53, 8116-8128
25. Chen, S.; Sun, Y. U. S. Process for hydrolyzing water-insoluble epoxides. Patent Application US 2004/0192976 A1. Sept. 30, 2004.
26. Wang, Z.; Cui, Y. T.; Xu, Z. B.; Qu, J. Hot water-promoted ring-opening of epoxides and aziridines by water and other nucleopliles J. Org. Chem. 2008, 73, 2270-2274
27. Ishii, Y.; Yamawaki, K.; Ura, T.; Yamada, H.; Yoshida, T.; Ogawa, M. Hydrogen-Peroxide Oxidation Catalyzed by Heteropoly Acids Combined with Cetylpyridinium Chloride-Epoxidation of Olefins and Allylic Alcohols, Ketonization of Alcohols and Diols, and Oxidative Cleavage of 1,2-Diols and Olefins J. Org. Chem. 1988, 53, 3587-3593
28. Wang, C. G., X.; Yu, M. Synthesis of fused bicyclic rings by tandem radical ring expansion/cyclization: Evaluating competing intramolecular reactions Tetrahedron 1998, 54, 8355-8370
29. Taber, D. F.; Ruckle, R. E. Cyclopentane construction by dirhodium tetraacetate-mediated intramolecular C-H insertion: Steric and electronic effects J. Am. Chem. Soc. 1986, 108, 7686-7693
30. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst. 1990, 82, 1107-1112
31. Boyd, M. R.; Paull, K. D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer discovery screen Drug Dev. Res. 1995, 34, 91-109
32. Tripathi, A.; Fornabaio, M.; Kellogg, G. E.; Gupton, J. T.; Gewirtz, D. A.; Yeudall, W. A.; Vega, N. E.; Mooberry, S. L. Docking and Hydropathic Scoring of Polysubstituted Pyrrole Compounds with Anti-Tubulin Activity Bioorg. Med. Chem. 2008, 16, 2235-2242
33. Nguyen, T. L.; McGrath, C.; Hermone, A. R.; Burnett, J. C.; Zaharevitz, D. W.; Day, B. W.; Wipf, P.; Hamel, E.; Gussio, R. A Common Pharmacophore for a Diverse Set of Colchicine Site Inhibitors Using a Structure-based Approach J. Med. Chem. 2005, 48, 6107-6116
34. De Martino, G.; Edler, M. C.; La Regina, G.; Coluccia, A.; Barbera, M. C.; Barrow, D.; Nicholson, R. I.; Chiosis, G.; Brancale, A.; Hamel, E.; Artico, M.; Silvestri, R. New Arylthioindoles: Potent Inhibitors of Tubulin Polymerization. 2. Structure-Activity Relationships and Molecular Modeling Studies J. Med. Chem. 2006, 49, 947-954
35. Molecular Operating Environment (MOE 2007.09) Chemical Computing Group, Inc., 1255 University St. Suite 1600, Montreal, Quebec, Canada H3B 3X3, www.chemcomp.com.
36. Bhattacharyya, B.; Panda, D.; Gupta, S.; Banerjee, M. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin Med. Res. Rev. 2008, 28, 155-183
37. Ravelli, R. B. G.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into Tubulin Regulation from a Complex with Colchicine and a Stathmin-like Domain Nature 2004, 428, 198-202
38. Lee, L.; Robb, L. M.; Lee, M.; Davis, R.; Mackay, H.; Chavda, S.; Babu, B.; O'Brien, E. L.; Risinger, A. L.; Mooberry, S. L. Design, synthesis, and biological evaluations of 2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoline analogs of combretastatin-A4 J. Med. Chem. 2010, 53, 325-334
39. Risinger, A. L.; Jackson, E. M.; Polin, L. A.; Helms, G. L.; LeBoeuf, D. A.; Joe, P. A.; Hopper-Borge, E.; Luduena, R. F.; Kruh, G. D.; Mooberry, S. L. The taccalonolides: Microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms Cancer Res. 2008, 68, 8881-8888
40. Hamel, E.; Lin, C. M. Separation of active tubulin and microtubule-associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles Biochemistry 1984, 23, 4173-4184
41. Hamel, E. Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin Cell Biochem. Biophys. 2003, 38, 1-22
42. Verdier-Pinard, P.; Lai, J.-Y.; Yoo, H.-D.; Yu, J.; Márquez, B.; Nagle, D. G.; Nambu, M.; White, J. D.; Falck, J. R.; Gerwick, W. H.; Day, B. W.; Hamel, E. Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells Mol. Pharmacol. 1998, 53, 62-76
43. Hamel, E.; Lin, C. M. Stabilization of the colchicine-binding activity of tubulin by organic acids Biochim. Biophys. Acta 1981, 675, 226-231